China SXT PharmaceuticalsSXTC 
-0.60%24h
China SXT Pharmaceuticals (SXTC) Stock Overview
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.
SXTC Stock Information
China SXT Pharmaceuticals (SXTC) Price Chart
China SXT Pharmaceuticals Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $0.835 | N/A |
| Market Cap | $472.22K | N/A |
| Shares Outstanding | 565.53K | 1259.78% |
| Employees | 78.00 | N/A |
| Shareholder Equity | 14.69M | -10.55% |
Valuation | 2023 | Change |
|---|---|---|
| P/S Ratio | 0.24 | N/A |
| P/B Ratio | 0.03 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | -0.4040 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $1.97M | N/A |
| Earnings | -$5.93M | N/A |
| Gross Margin | 0.2162 | N/A |
| Operating Margin | -2.84 | N/A |
| Net income margin | -3.01 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $29.55M | N/A |
| Total Debt | $3.76M | N/A |
| Cash on Hand | $17.37M | N/A |
| Debt to Equity | $1.01 | -2.95% |
| Cash to Debt | $4.62 | -39.06% |
| Current Ratio | $1.35 | 2.69% |
